This histogram enumerates side effects from a completed 2011 Phase 4 trial (NCT00611923) in the Flutamide ARM group. Side effects include: headache with 38%, stomach pain with 31%, dry skin with 23%, insomnia with 15%, nausea with 15%.
2 Treatment Groups
1 of 2
1 of 2
24 Total Participants · 2 Treatment Groups
Primary Treatment: Flutamide · Has Placebo Group · Phase < 1
Experimental Group · 1 Intervention: Flutamide · Intervention Types: Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Other
Drug Approval Stage
How many patients have taken this drug
Screening: ~3 weeks
Reporting: 6-9 months
Who is running the clinical trial?
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLead Sponsor
534 Previous Clinical Trials
31,088 Total Patients Enrolled
51 Trials studying Prostate Cancer
2,961 Patients Enrolled for Prostate Cancer
Daniel Song, M.D.Principal InvestigatorSKCCC at Johns Hopkins
Age 18+ · Male Participants · 5 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:
At least one biopsy core with Gleason 7 or higher disease.
Clinically palpable disease corresponding to (ipsilateral to) any involved core on biopsy.
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.